B. Metzler seel. Sohn & Co. Holding AG Invests $344,000 in United Therapeutics Co. (NASDAQ:UTHR)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 960 shares of the biotechnology company’s stock, valued at approximately $344,000.

A number of other institutional investors also recently added to or reduced their stakes in UTHR. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in shares of United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after buying an additional 33 shares in the last quarter. Toronto Dominion Bank grew its holdings in United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after purchasing an additional 37 shares during the last quarter. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of United Therapeutics by 14.0% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. boosted its position in shares of United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

UTHR stock opened at $372.89 on Monday. The business has a 50 day simple moving average of $365.06 and a 200-day simple moving average of $332.32. The firm has a market capitalization of $16.65 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.38 earnings per share. On average, equities research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Jefferies Financial Group raised their price objective on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Finally, Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $370.86.

Insider Buying and Selling at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This trade represents a 12.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $1,034,510.88. The trade was a 85.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 117,227 shares of company stock worth $43,671,320 over the last three months. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.